Immunotherapy

A new international study led by researchers at Moffitt Cancer Center, the Karolinska Institutet and the University of Texas MD Anderson Cancer Center has uncovered a surprising mechanism of resistance to immunotherapy: cancer's ability to injure nearby nerves.

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing in pediatric high-grade glioma tumors but not in normal brain tissues.

Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, and microenvironmental signaling interactions, are critical drivers of malignancy.

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option.

The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition...

The MHRA has approved teplizumab for adults and children aged 8 years and over, offering a potential 3-year delay in type 1 diabetes progression.

Panelists discuss evolving treatment strategies for metastatic melanoma with asymptomatic brain metastases, highlighting the superiority of PD-1 plus CTLA-4 combination therapy for durable intracranial responses, while noting that newer immunotherapy combinations like PD-1 plus LAG-3 show promise but require further evidence before altering current standards of care.

Mnt News RSS Feed

Researchers ask physicians to consider anti-IgLON5 disease if certain symptoms are present, as the only promising approach is early treatment.

Killer immune cells destroy cancer cells and cells infected by virus. These CD8+ T cells are activated after detection of viral infection or growth of "non-self" tumor cells.

Experts debate which patients with stage III dMMR colon cancer will benefit from the two treatment approaches.

MONDAY, Aug. 4, 2025 — Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks reluctant to give up the ubiquitous...

Cancer-associated fibroblasts (CAFs) – critical but enigmatic players in tumors – exhibit "paradoxical" effects on immunotherapy, according to a new review in Clinical and Translational Discovery.

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence through multiple pathways, including persistent stimulation by tumor-associated antigens, metabolic pathway alterations, activation of chronic inflammatory responses, proliferation of immunosuppressive cells, and T cell damage caused by tumor radiotherapy and chemotherapy.

Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple myeloma.

A comprehensive new review reveals both the promise and challenges of using fecal microbiota transplantation (FMT) to enhance cancer immunotherapy effectiveness.

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls.

The tumor microenvironment (TME) represents a highly complex system that encompasses cellular components (such as cancer cells, stromal cells, and immune cells) and non-cellular components (such as blood vessels and signaling molecules).

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

Head and neck squamous cell carcinomas (HNSCC) are a group of cancers that affect cells in and around our mouth and nose.

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment - immunotherapy - may help change the environment where cancer cells live, possibly helping the immune system respond more effectively.

A virus that typically infects black-eyed peas is showing great promise as a low-cost, potent cancer immunotherapy-and researchers are uncovering why.

MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why.Patients’ own autoantibodies – immune proteins traditionally associated with...

David Baker’s Nobel Prize-winning lab has developed a scalable AI pipeline to generate highly specific and easily manufacturable protein binders to enhance the immune system's ability to detect and fight disease. The post AI-Designed Proteins Enable Scalable Precision Immunotherapy appeared first on GEN - Genetic Engineering and Biotechnology News.

Salk Institute Professor Diana Hargreaves was named a 2025 All-Star Translational Award Program grantee by the V Foundation for Cancer Research.

​A UCL-sponsored clinical trial for patients newly diagnosed with glioblastoma, an aggressive form of brain cancer, has opened at UCLH's National Hospital for Neurology and Neurosurgery and Clinical Research Facility, in memory of Baroness Margaret McDonagh.

Study in humans and mice suggests patients’ autoantibodies may significantly influence response to immune checkpoint inhibitors, potentially boosting the likelihood of treatment success, as well as indicating cancer’s weak spots and pointing to therapeutic targets. The post Immunotherapy Response May Be Influenced by Patient’s Own Autoantibodies appeared first on GEN - Genetic Engineering and Biotechnology News.

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other localized treatments) has shown that one in five (19.6%) participants treated with STRIDE (Single Tremelimumab Regular Interval Durvalumab) a combination of two immunotherapies, remained alive after five years of follow-up versus one in 10 (9.4%) participants treated with sorafenib, a standard treatment for uHCC when the study was designed.

Glioblastoma breakthrough: 40-year-old dad is brain cancer-free after groundbreaking immunotherapy trial  Times of IndiaMan's deadly brain cancer tumor disappears after experimental drug trial  Fox NewsDad with deadly brain cancer that kills in a year is now cancer free after taking new drug  New York PostMan sees deadly brain cancer vanish after experimental treatment  The TelegraphDad’s aggressive brain cancer vanishes after taking new drug  The Independent

Glioblastoma breakthrough: 40-year-old dad is brain cancer-free after groundbreaking immunotherapy trial  Times of IndiaMan's deadly brain cancer tumor disappears after experimental drug trial  Fox NewsDad with deadly brain cancer that kills in a year is now cancer free after taking new drug  New York PostMan sees deadly brain cancer vanish after experimental treatment  The TelegraphDad’s aggressive brain cancer vanishes after taking new drug  The Independent

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to the treatment, leading to positive outcomes for patients, according to new research by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Netherlands Cancer Institute.

After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.

Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.

In a discussion at IBC East, Heather McArthur, MD, highlighted how immunotherapy is being utilized for patients with early-stage breast cancer.

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of leukemia cells – and developed a novel immunotherapy that can disrupt that loop to boost immune function and improve survival.

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.

Preschool oral immunotherapy significantly reduces parental food allergy anxiety and burden — changes that may ease their psychological distress and improve daily family functioning.

WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer.Unfortunately, that hope doesn’t extend to people without health insurance, a new study says.Immune checkpoint inh...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, a rare but life-threatening side effect of cancer immunotherapy, using an existing class of autoimmune drugs.

Researchers identified and tested in mice a potential new strategy to prevent, and potentially reverse, immune checkpoint inhibitor–induced type 1 diabetes mellitus using an existing class of autoimmune drugs. The post Autoimmune Disorder Therapy Drug Reverses Immunotherapy-Related Diabetes in Mouse Model appeared first on GEN - Genetic Engineering and Biotechnology News.

The results of research involving human data analysis and a study in mice indicate that corticosteroids are the main reason that immune checkpoint inhibitor therapy may fail in treating non-small cell lung cancer. The post Corticosteroids Reduce Effectiveness of Immunotherapy for NSCLC appeared first on GEN - Genetic Engineering and Biotechnology News.

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to new research by Keck Medicine of USC.

The MHRA has approved a new immunotherapy for BCG-unresponsive bladder cancer, offering a bladder-sparing alternative to cystectomy.

Advanced treatments, known as immunotherapies that activate T cells—our body's immune cells—to eliminate cancer cells, have shown limited efficacy as standalone therapies for glioblastoma, the most lethal form of brain tumor.

June 27, 2025 -- The U.S. Food and Drug Administration announced today that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor CAR T cell...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for recurrence after treatment.

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Researchers led by John T. Wilson, Vanderbilt University associate professor of chemical and biomolecular engineering and biomedical engineering, have developed a new approach using a molecularly designed nanobody platform that seeks to make immunotherapy more effective in the treatment of cancer.

A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit regardless of PD-L1 status.

“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.

Modulating microbiome composition after allogeneic hematopoietic stem cell transplantation may help oncologists prevent bloodstream infections posttreatment.

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on understanding the immune system's role in disease-is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies.

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence."

arXiv:2506.12185v1 Announce Type: new Abstract: In the past, the development of vaccines and immunotherapeutics relied heavily on trial-and-error experimentation and extensive in vivo testing, often requiring years of pre-clinical and clinical trials. Today, artificial intelligence (AI) and deep learning (DL) are actively transforming vaccine and immunotherapeutic design, by (i) offering predictive frameworks that support rapid, data-driven decision-making; (ii) increasingly being implemented as time- and resource-efficient strategies that integrate computational models, systems vaccinology, and multi-omics data to better phenotype, differentiate, and classify patient diseases and cancers; predict patients' immune responses; and identify the factors contributing to optimal vaccine and immunotherapeutic protective efficacy; (iii) refining the selection of B- and T-cell antigen/epitope targets to enhance efficacy and durability of immune protection; and (iv) enabling a deeper

arXiv:2506.09293v1 Announce Type: new Abstract: This article focuses on current and emerging therapeutics for CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy). CADASIL is an inherited vascular disease that impairs blood flow in the small cerebral vessels of the brain, leading to strokes and other neurological deficits. The disease is caused by a mutation in the NOTCH3 gene located on chromosome 19. NOTCH3 encodes a transmembrane receptor expressed on vascular smooth muscle cells. In CADASIL, mutations in the NOTCH3 gene lead to the accumulation and deposition of the receptor, affecting the number of cysteine residues in its extracellular domain. These mutations result in the loss or gain of a cysteine residue within the epidermal growth factor-like repeat (EGFr) domains of the NOTCH protein. Beyond traditional symptomatic treatments for stroke, this work highlights advances in disease modifying approaches including gene editing, cell

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the publication of a peer-reviewed study in The Journal of Immunology.

CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do not respond to the latest cancer treatments.

FRIDAY, June 6, 2025 — Immunotherapy combined with chemo can give people a fighting chance against stomach and esophageal cancers, a new clinical trial says.People treated with durvalumab and chemotherapy were much more likely to go into remission...

Panelists discuss how treatment selection is personalized based on patient characteristics, with relatlimab-nivolumab or monotherapy preferred for frail patients with low disease burden, while ipilimumab-nivolumab might be considered for patients with brain metastases despite its higher toxicity.

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune checkpoint inhibitors.

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment.

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

The University of Pittsburgh's Natasa Miskov-Zivanov, assistant professor of electrical and computer engineering, has received a prestigious Faculty Early Career Development (CAREER) Award of $581,503 from the National Science Foundation (NSF) for her project titled "Artificial Intelligence-Driven Framework for Efficient and Explainable Immunotherapy Design."

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Allogeneic CAR-T cell immunotherapy that targets aggressive blood cancers showed promising results alongside manageable side effects in Phase 1/2 clinical trial in patients with T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma. The post “Universal” CAR-T Immunotherapy Targets Relapsed/Refractory Blood Cancers appeared first on GEN - Genetic Engineering and Biotechnology News.

Panelists discuss how the dose-response relationship is more pronounced with ipilimumab than with PD-1 inhibitors, explaining why toxicity increases with higher ipilimumab doses while efficacy may not proportionally improve with higher PD-1 inhibitor doses.

Panelists discuss how the toxicity profiles of immunotherapy regimens are fundamentally similar in type but differ significantly in frequency and severity, with ipilimumab-containing regimens causing higher rates of serious adverse events, particularly colitis and hypophysitis.

arXiv:2505.23675v1 Announce Type: new Abstract: Accurately predicting immunotherapy response in Non-Small Cell Lung Cancer (NSCLC) remains a critical unmet need. Existing radiomics and deep learning-based predictive models rely primarily on pre-treatment imaging to predict categorical response outcomes, limiting their ability to capture the complex morphological and textural transformations induced by immunotherapy. This study introduces ImmunoDiff, an anatomy-aware diffusion model designed to synthesize post-treatment CT scans from baseline imaging while incorporating clinically relevant constraints. The proposed framework integrates anatomical priors, specifically lobar and vascular structures, to enhance fidelity in CT synthesis. Additionally, we introduce a novel cbi-Adapter, a conditioning module that ensures pairwise-consistent multimodal integration of imaging and clinical data embeddings, to refine the generative process. Additionally, a clinical variable conditioning

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce dramatic results when treating blood cancers like lymphoma and leukemia and shows promise against solid tumors.

A team identified herpes virus saimiri, which infects the T cells of squirrel monkeys, as a source of proteins that activate pathways in T cells that are needed to promote T cell survival.

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding groundbreaking projects, has awarded the University of Houston $3 million to set up a Cancer Immunotherapy Biomarker Core.

Our study investigated the role of astrocytes, an abundant cell type in the brain, in regulating an immune response against glioblastoma (GBM)-a highly aggressive brain cancer.

Panelists discuss how 2 key clinical trials, Checkmate 067 and RELATIVITY-047, established the efficacy of different immunotherapy combinations while highlighting the significant difference in toxicity profiles between ipilimumab plus nivolumab (60% grade 3/4 toxicity) versus relatlimab plus nivolumab (19% grade 3/4 toxicity).

Panelists discuss how monotherapy may still be appropriate for certain patient populations including those with desmoplastic melanoma, solid organ transplants, severe autoimmune disease, and older patients where the toxicity risk of combination therapy may outweigh benefits.

University of Texas at Dallas bioengineers, in collaboration with UT Southwestern Medical Center researchers, are developing an enhanced light-activated immunotherapy approach that could one day treat patients with stomach cancer that has spread throughout the abdomen.

A study published today in the Journal of Cancer Survivorship found that cancer survivors receiving high-cost immunotherapy treatments were more likely to face financial hardship, leading to increased instances of being unable to afford care and taking fewer medications due to cost.

Panelists discuss how the treatment paradigm for melanoma has evolved to favor upfront dual checkpoint blockade over targeted therapy, except in specific cases where rapid response is needed for symptomatic patients with high LDH.

Nicholas Blondin, MD, discusses the latest advancements in immunotherapy for brain cancer as well as emerging strategies, including CAR T-cell therapy.

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.

arXiv:2505.06067v1 Announce Type: new Abstract: Newcastle Disease Virus (NDV), classified as Avian orthoavulavirus 1 (avian paramyxovirus type 1), is a promising oncolytic agent that selectively targets and destroys cancer cells while sparing normal tissues. Its oncoselectivity exploits cancer-specific defects in antiviral defenses, particularly impaired Type I interferon signaling, and dysregulated apoptotic pathways, enabling robust viral replication and cytotoxicity in malignancies such as breast, colorectal, and melanoma. NDV induces intrinsic and extrinsic apoptosis through caspase activation and triggers immunogenic cell death via damage-associated molecular patterns, stimulating potent antitumours immune responses. Additionally, NDVs potential as a vaccine vector, expressing tumours-associated antigens, offers prospects for prophylactic and therapeutic cancer applications. This review provides a comprehensive analysis of NDVs morphology, classification, and molecular biology,

Researchers from MIT and Dana-Farber Cancer Institute have discovered that a class of peptides expressed in pancreatic cancer cells could be a promising target for T-cell therapies and other approaches that attack pancreatic tumors.

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’  CNNMedicine Spares Cancer Patients From Grisly Surgeries and Harsh Therapies  The New York TimesA New Immune Treatment May Work Against Several Cancer Types  Time MagazineImmunotherapy drug capable of eliminating tumors in some early stage cancers: Study  ABC NewsAlternative cancer treatment could replace chemo and surgery, study suggests  Fox News

Immunotherapy helps certain cancer patients avoid surgery: ‘We hope this is the future’  CNNMedicine Spares Cancer Patients From Grisly Surgeries and Harsh Therapies  The New York TimesA New Immune Treatment May Work Against Several Cancer Types  Time MagazineImmunotherapy drug capable of eliminating tumors in some early stage cancers: Study  ABC NewsAlternative cancer treatment could replace chemo and surgery, study suggests  Fox News

Patients who were most likely to discontinue therapy had allergy to milk, sesame, and egg — all of which were associated with higher severe reaction rates.

Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need for surgery in some patients.

Immunotherapy drug capable of eliminating tumors in some early-stage cancers: Study  ABC NewsImmunotherapy Drug Spares Cancer Patients From Grisly Surgeries and Harsh Therapies  The New York TimesA New Immune Treatment May Work Against Several Cancer Types  Time MagazineFor some cancer patients, immunotherapy may be way to skip surgery and chemo  NBC NewsAACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors  The ASCO Post

Immunotherapy drug capable of eliminating tumors in some early-stage cancers: Study  ABC NewsImmunotherapy Drug Spares Cancer Patients From Grisly Surgeries and Harsh Therapies  The New York TimesA New Immune Treatment May Work Against Several Cancer Types  Time MagazineFor some cancer patients, immunotherapy may be way to skip surgery and chemo  NBC NewsAACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors  The ASCO Post